Bone Biologics (BBLG) - Capital Market Series w/ Jeff Frelick, CEO | President

Capital Market Series - 013 - Bone Biologics NASDAQ: BBLG Website: https://www.bonebiologics.com/ In this episode of Capital Market Series, we bring you a NASDAQ story focused on improving the living conditions of degenerative bone problems that arise with age and/or abuse of body. With us is the President and CEO of BoneBiologics to discuss the novel research in providing a less invasive and efficient mechanisms to produce equal or better results that are currently on the market. With trials moving into the human phase in Australia, BoneBiologics is moving in the right direction for FDA approval. Jeff Frelick - Chief Executive Officer | President Jeffrey Frelick assumed the CEO and President role in June 2019. Previously he served as the Chief Operating Officer of Bone Biologics Inc. since August 2015. Frelick brings more than 25 years of med-tech experience to the position. He spent the past 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Frelick worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinson’s Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Frelick earned a B.S. in Biology from the University of Pittsburgh and an M.B.A. from Suffolk University’s Sawyer Business School. Bone Biologics is a publicly traded company based in Burlington, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Currently preparing for pilot clinical trial: - Clearance to move into human studies in Australia - Potential commercialization into $3 billion dollar orthobiologics market pending - Successful completion of pivotal human studies in U.S Website: https://www.bonebiologics.com/ https://www.newgenmindset.com/ Instagram: @newgenmindsetpod X: @newgen_mindset Disclaimer: None of the information provided in this episode should be considered investment advice and should only be viewed for informational purposes. NewGenMindset is not a broker or a licensed provider of financial services. Any claims made in this episode to any listener should not be regarded as offering personalized legal or investment counseling. Any investments made in any companies should be consulted with a licensed financial professional from here on. #health #research #medicaltechnology #surgery #bones #medical #research #investment #stocks #stockmarket #stockmarketnews #usa #market